KoenraadDe GeestMD

PubMed

• 36 citations
  Matrix-free 3D culture supports human follicular development from the unilaminar to the antral stage in vitro yielding morphologically normal metaphase II oocytes.
  Fuhua Xu, Maralee S. Lawson, Yukie Bean, Alison Y. Ting, Tanja Pejovic
  Human Reproduction. 2021-04-20
• 61 citations
  Efficacy and safety of bevacizumab in recurrent sex cord‐stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group
  Jubilee Brown, William E. Brady, Julian C. Schink, Linda Van Le, Mario M. Leitao
  Cancer. 2014-02-01
• 20 citations
  Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
  N. Nadkarni, Koen De Geest, T. Neff, Barry De Young, David Bender
  Cancer Letters. 2013-04-30

Journal Articles

• Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.  
  Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, De Geest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA, Cole SW, Sood AK, Lubaroff D, J Clin Oncol. 2008; 26(29):4820-7
• A Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group study.  
  Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, De Geest K, Miller BE, Susumu N, Ueland FR, J Clin Oncol. 28 (16): 2727-31
• A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study.  
  Aghajanian C, Blessing JA, Darcy KM, Reid G, De Geest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W, Gynecol Oncol 115 (2): 215-20
• A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxe...  
  Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, De Geest K, Lee R, Montag A, Gynecol Oncol 112 (3):543-52
• Depression, social support, and beta-adrenergic transcription control in human ovarian cancer.  
  Lutgendorf SK, De Geest K, Sung CY, Arvealo JM, Penedo F, Lucci III J, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SW, Brain Behav Immun 2009;23:176-183
• Glucose as a prognostic factor in ovarian carcinoma.  
  Lamkin DM, Spitz DR, Zimmerman B, De Geest K, Lubaroff DM, Sood AK, Lutgendorf SK, Cancer, 2009; 115 (5):1021-7
• DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage.  
  Watts GS, Futscher BW, Holtan N, De Geest K, Domann FE, Rose SL, BMC Med Genomics 2008;1(1):47
• The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992-2002.  
  Ahmed A, Zamba G, De Geest K, Lynch CF, Gynecol Oncol 2008;111(1):35-40
• Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma.  
  Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JMG, Penedo F, De Geest K, Langley RR, Lucci III JA, Cole SW, Lubaroff DM, Sood AK, Clin Cancer Res. 2008;14(21):6839-46
• Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.  
  Sood AK, Halder J, Armaiz-Pena G, Nick AM, Stone RL, Spannnuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MMK, McIntyre BW, Diaz-Montero CM, Jennings MB, Lin..., J Clin Invest. 120 (5):1515-23
• Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.  
  Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley R, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G..., J Natl Cancer Inst 2008;100(5):359-72
• HLA class I antigen processing machinery component expression and intramural T-cell infiltrate as independent prognostic markers in ovarian carcinoma.  
  Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK, Clin Cancer Res 2008;14(11):3372-9
• Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.  
  Hensley ML, Blessing J, De Geest K, Abulafia O, Rose P, Homesley HD, Gynecol Oncol 2008;109(3):323-8
• Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: A phase I and feasibility trial of the Gynecologic Oncolog...  
  Morgan MA, Darcy KM, Rose PG, De Geest K, Bookman MA, Aikins JK, Sill MW, Manneul RS, Allievi C, Egorin MJ, Gynecol Oncol 2008;110(3):329-35
• Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients.  
  Lutgendorf SK, Lamkin DM, De Geest K, Anderson B, Minh Dao, McGinn S, Zimerman B, Maiseri H, Sood AK, Lubaroff, DM, Brain Behav Immun 22 (6):890-900
• Positive psychosocial factors and NKT cells in ovarian cancer patients.  
  Lamkin DM, Lutgendorf SK, McGinn S, Minh Dao, Maiseri H, De Geest K, Sood AK, Lubaroff DM, Brain Behav Immun 22 (1):65-73
• A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: A Gynecologic Oncology Group ...  
  Rose PG, De Geest K, McMeekin S, Fusco N, Gynecol Oncol 107 (2): 274-79
• Quality of life and mental health in cervical and endometrial cancer survivors.  
  Bradley S, Rose S, Lutgendorf S, Costanzo E, Sorosky J, De Geest K, Anderson B, Gynecol Oncol 100(3):479-86
• A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor enzastaurin and evaluation of markers with potential predictive and prognostic value...  
  Usha l, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, and Godwin AK, Gynecol Oncol 121: 455-461
• The role of LEF1 in endometrial gland formation and carcinogenesis.  
  Shelton D, Fornalik H, Neff T, Park SY, Bender D, De Geest K, Liu X, Xie W, Meyerholz D, Engelhardt J, Goodheart M, PloS ONE 7(7) e40312. doi:10.1371/journal.pone.0040312
• Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability.  
  Schrepf A ,Clevenger L, Christensen D, De Geest K, Bender D, Ahmed A, Goodheart M, Dahmoush L, Penedo F, Lucci J, Ganjei-Azar P, Mendez L, Markon K, Lubaroff D, Thaker..., Cancer 2012
• Aspirin and Warfarin are associated with Improved Overall Survival in Medically Inoperable Endometrial Cancer Patients Treated with Radiation Therapy.  
  Fornalik H, Goodheart MJ, Buekers TE, DeGeest K, Jacobson GM, Gynecol Obstetric S4:002
• A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival.  
  Shamshiraz AA, Buekers T, DeGeest K, Bender D, Zamba G, Goodheart MJ, Int J Gynecol Cancer, 2011(7):1232-40
• Intraoperative autologous blood transfusion during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial.  
  Engle D, Conner J, Morris P, Bender D, De Geest K, Ahmed A, Goodheart M, Arch Gynecol Obstet 2012 DOI 10.1007/s00404-012-2351-1
• A phase II study of evaluation of a Urokinase-Derived Peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritone...  
  Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB, Gynecol Oncol 125: 635-39
• Join now to see all

Books/Book Chapters

• Estrogen receptors in breast cancer. 
  Chapter: Endocrinological Cancer. Ovarian function and disease 
  De Geest K, De Boever J, Vandekerckhove DEditors: Adlercreutz H, Bulbrook P, Van der Molen H, Vermeulen A, Sciarra F.Excerpta Medica, Amsterdam, Oxford Princeton
• Zusatzund Nachbehandlung des Mammakarzinoms. 
  Chapter: Stellenwert der Mammographie und der Thermographie in der Diagnose von gutartigen und bosartigen Mammatumoren 
  De Geest K., Parewijck W., Vandekerckhove DEditors: H. Jung, B. Liedtke.Ferdinand Enke Verslag , Stuttgart
• Recepteurs hormonaux et pathologie mammaire. 
  Chapter: Valeur pronostique des recepteurs d’estradiol dans le cancer du sein operabl 
  De Geest K., Vandekerckhove D., De Boever JEditors: H. Serment, P.M. Martin.Medecine et Sciences Internationales, Paris
• Cell a tissue culture laboratory procedures. 
  Chapter: Growth and differentiation of endocervical and ectocervical epithelial cells 
  Turyk M, Wilbanks G, De Geest KJ. Wiley & Sons publ, Chichester, UK
• Join now to see all

Abstracts/Posters

• Estrogen receptor in normal and malignant breast tissue.
  De Boever J., De Geest K., Vandekerckhove D, Ninth Meeting of the International Study Group for Steroid Hormones, Rome, Italy
• Normoprolactinemia and infertility.
  De Geest K., Dhondt M., Vandekerckhove D, Reproductive Physiology. St. Mary’s College, Oxford, U.K
• Valeur pronostique des recepteurs d’oestradiol.
  Vandekerckhove D., De Geest K., De Boever J, 2e Journees de la Societe Francaise de senologie et de pathologie mammaire, Marseille, France